These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29498118)

  • 21. Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases.
    Palhano FL; Leme LP; Busnardo RG; Foguel D
    J Biol Chem; 2009 Jan; 284(3):1443-53. PubMed ID: 18984591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transthyretin stability is critical in assisting beta amyloid clearance- Relevance of transthyretin stabilization in Alzheimer's disease.
    Alemi M; Silva SC; Santana I; Cardoso I
    CNS Neurosci Ther; 2017 Jul; 23(7):605-619. PubMed ID: 28570028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants.
    Schwarzman AL; Tsiper M; Wente H; Wang A; Vitek MP; Vasiliev V; Goldgaber D
    Amyloid; 2004 Mar; 11(1):1-9. PubMed ID: 15185492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z; Colón W; Kelly JW
    Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
    Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
    Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.
    Ribeiro CA; Oliveira SM; Guido LF; Magalhães A; Valencia G; Arsequell G; Saraiva MJ; Cardoso I
    J Alzheimers Dis; 2014; 39(2):357-70. PubMed ID: 24169237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis.
    Ciccone L; Nencetti S; Tonali N; Fruchart-Gaillard C; Shepard W; Nuti E; Camodeca C; Rossello A; Orlandini E
    Bioorg Med Chem; 2020 Sep; 28(18):115673. PubMed ID: 32828431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease.
    Wati H; Kawarabayashi T; Matsubara E; Kasai A; Hirasawa T; Kubota T; Harigaya Y; Shoji M; Maeda S
    Brain Pathol; 2009 Jan; 19(1):48-57. PubMed ID: 18429966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling transthyretin (TTR) amyloid diseases, from monomer to amyloid fibrils.
    Criddle RS; Hansen LD; Woodfield BF; Tolley HD
    PLoS One; 2024; 19(6):e0304891. PubMed ID: 38843135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization.
    Raghu P; Reddy GB; Sivakumar B
    Arch Biochem Biophys; 2002 Apr; 400(1):43-7. PubMed ID: 11913969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.
    Kim B; Park H; Lee SK; Park SJ; Koo TS; Kang NS; Hong KB; Choi S
    Eur J Med Chem; 2016 Nov; 123():777-787. PubMed ID: 27541261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity.
    Redondo C; Damas AM; Saraiva MJ
    Biochem J; 2000 May; 348 Pt 1(Pt 1):167-72. PubMed ID: 10794728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?
    Li X; Buxbaum JN
    Mol Neurodegener; 2011 Nov; 6():79. PubMed ID: 22112803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils.
    Cardoso I; Goldsbury CS; Müller SA; Olivieri V; Wirtz S; Damas AM; Aebi U; Saraiva MJ
    J Mol Biol; 2002 Apr; 317(5):683-95. PubMed ID: 11955017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
    Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
    Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transthyretin binds amyloid beta peptides, Abeta1-42 and Abeta1-40 to form complex in the autopsied human kidney - possible role of transthyretin for abeta sequestration.
    Tsuzuki K; Fukatsu R; Yamaguchi H; Tateno M; Imai K; Fujii N; Yamauchi T
    Neurosci Lett; 2000 Mar; 281(2-3):171-4. PubMed ID: 10704770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics of inhibition of beta-amyloid aggregation by transthyretin.
    Liu L; Murphy RM
    Biochemistry; 2006 Dec; 45(51):15702-9. PubMed ID: 17176092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transthyretin-derived peptides as β-amyloid inhibitors.
    Cho PY; Joshi G; Johnson JA; Murphy RM
    ACS Chem Neurosci; 2014 Jul; 5(7):542-51. PubMed ID: 24689444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
    Lashuel HA; Wurth C; Woo L; Kelly JW
    Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.